1. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
2. Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3):585–95.
3. Otsuka Pharmaceutical Co. Ltd. Rexulti® (brexpiprazole) tablets for oral use: US prescribing information. 2015. http://www.otsuka-us.com . Accessed 6 Aug 2015.
4. US Food and Drug Administration. FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder [media release]. 13 July 2015. http://www.fda.gov .
5. Otsuka Pharmaceutical Co. Ltd. US FDA approves Otsuka and Lundbeck’s Rexulti® (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia [media release]. 10 July 2015. http://www.otsuka.co.jp .